FDA Drops New Cheat Sheets for Generic Drug Makers
Published Date: 5/22/2026
Notice
Summary
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
Draft BE Study Design Guidance
The FDA posted new draft product-specific guidances that provide product-specific recommendations on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). These draft guidances are available on FDA's website and are intended for industry use in planning BE studies.
Specific Drugs Listed For Guidance
FDA published lists of active ingredients for which new draft product-specific guidances (Table 1) and revised draft guidances (Table 2) are available, including drugs such as amlodipine besylate, telmisartan, carboplatin, warfarin sodium, albuterol sulfate, aripiprazole, and many others. Companies developing generic versions of the listed active ingredients can consult the corresponding draft guidances posted on FDA's website.
Public Comment Deadline Set
FDA is accepting electronic or written comments on these draft guidances and must receive comments by July 21, 2026 for consideration before FDA begins work on the final versions. Comments submitted to https://www.regulations.gov will be posted publicly unless submitted as confidential written/paper submissions following FDA instructions.
Final Guidances Reflect FDA Thinking
The notice states that when finalized, these guidances will represent FDA's current thinking on product-specific BE study design to support ANDAs, but they do not establish any rights and are not binding on FDA or the public. The notice also states you may use an alternative approach if it satisfies applicable statutes and regulations.
FDA Will Consider Cost Comments
FDA will consider comments on costs or cost savings that the guidances may generate as it develops the final guidances, noting relevance to Executive Order 14192. Stakeholders may submit cost-related comments for FDA's consideration during finalization.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
2026-10188 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing Technologies Designation Program
The FDA is updating how it collects info about drug making to keep medicines safe and high-quality. This affects drug makers who must follow good manufacturing rules and may see some changes in paperwork. Comments on these updates are open until June 22, 2026, so industry folks have time to weigh in before any new rules kick in.
Previous / Next Documents
Previous: 2026-10275 — UL LLC: Application for Expansion of Recognition and Proposed Modification to the NRTL Program's List of Appropriate Test Standards
UL LLC wants to expand its role as a trusted safety tester and add a new test standard to the official list. This means more products can get checked faster and safer, helping businesses and workers alike. If you have thoughts, speak up by June 8, 2026—no fees or costs are changing right now!
Next: 2026-10278 — National Vaccine Injury Compensation Program: Revised Amount of the Average Cost of a Health Insurance Policy
The National Vaccine Injury Compensation Program just updated the average monthly cost of a health insurance policy to $742.53. This change affects anyone involved in vaccine injury claims and helps keep compensation fair and up-to-date. The new amount took effect as soon as it was sent to the Court in 2026, reflecting a 5% increase from last year.